Compare AbCellera Biologics Inc (ABCL) vs Moody's Corporation (MCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Moody's Corporation — how do they compare? AbCellera Biologics Inc trades at $8.94 (market cap $2.85B), while Moody's Corporation trades at $476.73 (market cap $82.80B). The key difference: Moody's Corporation is far larger — about 29.1× AbCellera Biologics Inc's market cap, and Moody's Corporation pays a 0.86% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | MCO | |
|---|---|---|
Market Cap | $2.85B | $82.80B |
Sector | Health | Financials |
52-Week High | $9.76 | $539.61 |
52-Week Low | $2.78 | $412.23 |
Enterprise Value | $2.45B | $88.83B |
Dividend Yield | — | 0.86% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABCL's stock surged 6.13% to $6.93, driven by positive Phase 2 trial results for its menopause drug ABCL635, which showed an 83% reduction in hot flashes. Despite a bullish technical signal and strong analyst consensus (91.67% buy ratings), the company faces fundamental challenges with a net income margin of -248.84% and negative cash flow from operations. Revenue declined from $485M in 2022 to $75M in 2025, though recent news highlights potential from clinical advancements and a collaboration with Vertex.
The outlook is mixed: near-term optimism hinges on drug development success, but high valuation ratios (P/S of 31.63) and persistent losses pose risks. Investors should weigh the 54% upside to the $10.67 price target against cash burn and competitive pressures in biotech.
MCO trades at $477.75, up 0.98% on the day, with a bullish technical signal and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $4.68 versus $4.26 expected, driven by robust debt issuance and analytics demand. Revenue growth accelerated to 15% year-over-year, with net income margin expanding to 34.25%. The stock is supported by a consensus price target of $561.88, indicating 17.6% upside potential, and positive analyst sentiment with 56% buy ratings.
Outlook remains positive due to consistent earnings beats, high profitability, and strategic positioning in credit ratings. Risks include elevated valuation multiples, such as a P/E of 30.31, and dependence on capital market activity. Investors should weigh growth prospects against potential macroeconomic headwinds affecting debt issuance volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
